QT Imaging Holdings Stock Price, News & Analysis

QT Imaging Holdings, Inc. (OTCQB: QTIH) is a healthcare company in the medical devices industry that focuses on the research, development, and commercialization of body imaging systems. According to the company’s public disclosures, its technology uses low frequency sound waves for medical imaging, with an emphasis on breast imaging applications. QT Imaging describes its strategy around the idea that medical imaging is essential for the detection, diagnosis, and treatment of disease, and that such imaging should be safe, affordable, accessible, and centered on the patient’s experience.

The company is frequently described in its news releases as being dedicated to transforming breast health management through radiation-free imaging technology. A core product highlighted in multiple announcements is the QTI Breast Acoustic CT™ scanner, which the company notes is an FDA-cleared system. QT Imaging states that this scanner is designed to provide breast imaging without compression, contrast administration, or harmful ionizing radiation, and to deliver a three-dimensional view of breast anatomy using quantitative transmission imaging and volumetric ultrasound techniques.

Business focus and technology approach

QT Imaging characterizes itself as a medical device company building an imaging platform around quantitative ultrasound and low frequency sound waves. In its public statements, the company links this technology to an evolving platform that incorporates AI/ML and biomarker science for breast imaging. Management commentary in news releases describes a transformation from being primarily a "scanner company" toward a software and biomarker-driven medical imaging franchise, with an ecosystem that can learn from imaging data over time.

The company’s communications also reference a Cloud SaaS Platform that is intended to deliver imaging-related services. In a collaboration announcement with Intelerad Medical Systems, QT Imaging explains that its Breast Acoustic CT™ scanners are being integrated with cloud-based picture archiving and communication systems (PACS) to support research networks and commercial installations. This cloud platform is described as a framework for deploying future AI/ML algorithms, including modules for quantitative feature extraction and diagnostic decision support.

Breast Acoustic CT™ and patient-centered design

Across several press releases, QT Imaging emphasizes that its breast imaging technology is radiation-free, contrast-free, and compression-free. The company positions these characteristics as aligned with its goal that imaging should be safe and centered on the patient’s experience. Public descriptions of the QTI Breast Acoustic CT™ scanner highlight its use as a non-invasive breast imaging technology that provides volumetric information about breast anatomy using low frequency sound waves, rather than ionizing radiation.

The company’s Chief Medical Officer has been featured in announcements about educational seminars on Quantitative Transmission Imaging Technology, which QT Imaging presents as a potential future direction for breast imaging with safe volumetric ultrasound. These communications underscore the firm’s focus on quantitative, volumetric, ultrasound-based imaging for breast health management.

Commercialization and distribution framework

QT Imaging describes itself as being in the commercialization phase of its body imaging systems. In its news releases, the company reports shipping QTI Breast Acoustic CT™ scanners to customers and refers to distribution agreements with partners. For example, it has disclosed an Amended Distribution Agreement with NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, and an exclusive distribution agreement with Gulf Medical Co. in Saudi Arabia for QTI Breast Acoustic CT™ scanners and user subscriptions to the QTI Cloud Platform. These agreements are cited in connection with shipment plans and revenue outlooks related to scanner deliveries.

The company has also announced a strategic collaboration with Intelerad Medical Systems to deploy InteleShare Research PACS and Cloud PACS across its clinical research and commercial networks. QT Imaging states that this collaboration is intended to enable research institutions and clinical sites to upload, store, anonymize, and share imaging data efficiently, and to support its cloud-based SaaS delivery model for imaging data and algorithms.

Corporate and capital markets profile

QT Imaging Holdings, Inc. is identified in SEC filings as a Delaware corporation. The company’s common stock trades on the OTCQB Venture Market under the ticker symbol QTIH. In its filings, QT Imaging indicates that it is an emerging growth company as defined under U.S. securities regulations. The company has filed a registration statement on Form S-1 and an amendment on Form S-1/A, and has used multiple Form 8-K current reports to disclose material events, including financing transactions, pro forma financial information, and changes to its capital structure.

In 2025, QT Imaging reported entering into a private placement (PIPE) financing for gross proceeds of approximately $18 million, and described the use of proceeds as including repayment of a portion of a senior secured term loan and funding for U.S. and global go-to-market activities and deployment of the QTI Cloud Platform. The company has also disclosed the implementation of a 3:1 reverse stock split of its common stock, effective October 23, 2025, with split-adjusted trading on the OTCQB beginning October 24, 2025. These capital markets actions have been documented in its Form 8-K filings and related press releases.

Financial reporting and growth commentary

QT Imaging issues periodic press releases discussing its revenue from scanner shipments and its financial position. For example, it has reported quarterly revenue associated with shipments of QTI Breast Acoustic CT™ scanners and has referenced year-over-year revenue growth and shipment volumes. The company has also furnished unaudited pro forma condensed consolidated financial statements via Form 8-K filings, which incorporate the effects of financing transactions and debt repayments on its balance sheet and results of operations.

Management commentary in these releases frames certain periods as transitional, moving from early commercialization to broader execution, and links financial performance to market adoption of its scanners and to the evolution of its imaging platform. The company also discusses non-GAAP financial measures such as EBITDA and Adjusted EBITDA, explaining how these metrics are calculated and how they are used by management, while noting their limitations and the fact that they are not a substitute for GAAP measures.

Research, clinical, and educational activities

QT Imaging’s public communications highlight its involvement in clinical research networks and major medical imaging conferences. The company has announced participation in the Radiological Society of North America (RSNA) annual meeting, including seminars on its quantitative transmission imaging technology and live demonstrations of its FDA-cleared QTI Breast Acoustic CT™ scanner. These activities are presented as opportunities to showcase the technology to radiology and oncology professionals and to support clinical adoption.

The collaboration with Intelerad is also described as supporting multi-institutional research trials by providing tools to access anonymized breast images, perform measurements, and manage research workflows. QT Imaging positions its cloud-based infrastructure as a way to connect scanners with research institutions and clinical sites, and as a pathway for delivering future AI/ML-based imaging tools.

Regulatory filings and governance

Through its SEC filings, QT Imaging provides details on its capital structure, warrants, convertible instruments, and earnout arrangements. The S-1 and S-1/A registration statements, together with multiple Form 8-K filings, describe items such as private placements, credit agreements, warrant repurchases, and amendments to its certificate of incorporation. The company has also disclosed stockholder approvals for corporate actions, including the reverse stock split, and the subsequent filing of the related certificate of amendment in Delaware.

QT Imaging identifies itself as an emerging growth company, which affects certain reporting and compliance provisions under U.S. securities law. The company uses its investor presentations and SEC reports to provide supplemental product and operational information to the market, and it periodically updates investors through earnings press releases and conference calls.

Position within the healthcare and medical devices sector

Within the broader healthcare sector, QT Imaging is categorized as a medical devices company with a specific focus on breast imaging and body imaging systems using low frequency sound waves. Its public statements emphasize radiation-free, contrast-free, and compression-free breast imaging, and the development of a cloud-enabled imaging platform that incorporates quantitative ultrasound, AI/ML techniques, and biomarker science. The company’s strategy, as described in its own materials, is to improve global health outcomes by making imaging safer and more accessible while maintaining a focus on the patient experience.